Anti-CD25 antibodies has been investigated as cancer therapy via at least two mechanisms: (1) directly targeting lymphoma cells expressing high level of CD25, such as ALCL [25,41]; (2) depleting Tregs to enhance the host anti-tumor immune response. The gene discussed is IL2RA; the disease is cancer.